Literature DB >> 22955280

Activation of nuclear factor κB (NF-κB) in prostate cancer is mediated by protein kinase C epsilon (PKCepsilon).

Rachana Garg1, Jorge Blando, Carlos J Perez, HongBin Wang, Fernando J Benavides, Marcelo G Kazanietz.   

Abstract

Protein kinase C ε (PKCε) has emerged as an oncogenic kinase and plays important roles in cell survival, mitogenesis and invasion. PKCε is up-regulated in most epithelial cancers, including prostate, breast, and lung cancer. Here we report that PKCε is an essential mediator of NF-κB activation in prostate cancer cells. A strong correlation exists between PKCε overexpression and NF-κB activation status in prostate cancer cells. Moreover, transgenic overexpression of PKCε in the mouse prostate causes preneoplastic lesions that display significant NF-κB hyperactivation. PKCε RNAi depletion or inhibition in prostate cancer cells diminishes NF-κB translocation to the nucleus with subsequent impairment of both activation of NF-κB transcription and induction of NF-κB responsive genes in response to the proinflammatory cytokine tumor necrosis factor α (TNFα). On the other hand, PKCε overexpression in normal prostate cells enhances activation of the NF-κB pathway. A mechanistic analysis revealed that TNFα activates PKCε via a C1 domain/diacylglycerol-dependent mechanism that involves phosphatidylcholine-phospholipase C. Moreover, PKCε facilitates the assembly of the TNF receptor-I signaling complex to trigger NF-κB activation. Our studies identified a molecular link between PKCε and NF-κB that controls key responses implicated in prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955280      PMCID: PMC3481351          DOI: 10.1074/jbc.M112.398925

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  A novel cross-talk in diacylglycerol signaling: the Rac-GAP beta2-chimaerin is negatively regulated by protein kinase Cdelta-mediated phosphorylation.

Authors:  Erin M Griner; M Cecilia Caino; Maria Soledad Sosa; Francheska Colón-González; Michael J Chalmers; Harald Mischak; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

2.  Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C.

Authors:  S Wang; M G Kazanietz; P M Blumberg; V E Marquez; G W Milne
Journal:  J Med Chem       Date:  1996-06-21       Impact factor: 7.446

Review 3.  Rel/NF-kappa B and I kappa B proteins: an overview.

Authors:  M J May; S Ghosh
Journal:  Semin Cancer Biol       Date:  1997-04       Impact factor: 15.707

4.  Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer.

Authors:  Moammir H Aziz; Herbert T Manoharan; Dawn R Church; Nancy E Dreckschmidt; Weixiong Zhong; Terry D Oberley; George Wilding; Ajit K Verma
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

5.  Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.

Authors:  Courtney R Lavalle; Karla Bravo-Altamirano; Karthik V Giridhar; Jun Chen; Elizabeth Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  BMC Chem Biol       Date:  2010-05-05

6.  p23/Tmp21 differentially targets the Rac-GAP beta2-chimaerin and protein kinase C via their C1 domains.

Authors:  Hongbin Wang; Marcelo G Kazanietz
Journal:  Mol Biol Cell       Date:  2010-02-17       Impact factor: 4.138

7.  PKC-delta and -epsilon regulate NF-kappaB activation induced by cholecystokinin and TNF-alpha in pancreatic acinar cells.

Authors:  Akihiko Satoh; Anna S Gukovskaya; Jose M Nieto; Jason H Cheng; Ilya Gukovsky; Joseph R Reeve; Tooru Shimosegawa; Stephen J Pandol
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-04-29       Impact factor: 4.052

8.  Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma.

Authors:  Pablo J Fernandez-Marcos; Shadi Abu-Baker; Jayashree Joshi; Anita Galvez; Elias A Castilla; Marta Cañamero; Manuel Collado; Carmen Saez; Gema Moreno-Bueno; Jose Palacios; Michael Leitges; Manuel Serrano; Jorge Moscat; Maria T Diaz-Meco
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-26       Impact factor: 11.205

9.  miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.

Authors:  Paolo Gandellini; Marco Folini; Nicole Longoni; Marzia Pennati; Mara Binda; Maurizio Colecchia; Roberto Salvioni; Rosanna Supino; Roberta Moretti; Patrizia Limonta; Riccardo Valdagni; Maria Grazia Daidone; Nadia Zaffaroni
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

Review 10.  Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms.

Authors:  M Veronica Gavrielides; Anita F Frijhoff; Claudio J Conti; Marcelo G Kazanietz
Journal:  Curr Drug Targets       Date:  2004-07       Impact factor: 3.465

View more
  33 in total

1.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.

Authors:  Rachana Garg; Jorge M Blando; Carlos J Perez; Martin C Abba; Fernando Benavides; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

2.  DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.

Authors:  Lian Zhang; Qian Zhang; LiLi Li; Zhaohui Wang; Jianming Ying; Yu Fan; Qun He; Tianjing Lv; Wenke Han; Jun Li; Yang Yang; Ben Xu; Lu Wang; Qianling Liu; Yinghao Sun; Yinglu Guo; Qian Tao; Jie Jin
Journal:  J Mol Med (Berl)       Date:  2015-02-05       Impact factor: 4.599

Review 3.  A critical review of assays for hazardous components of air pollution.

Authors:  Henry Jay Forman; Caleb Ellicott Finch
Journal:  Free Radic Biol Med       Date:  2018-01-31       Impact factor: 7.376

4.  Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.

Authors:  Bilal Bin Hafeez; Joseph W Fischer; Ashok Singh; Weixiong Zhong; Ala Mustafa; Louise Meske; Mohammad Ozair Sheikhani; Ajit Kumar Verma
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-27

Review 5.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

6.  PKCε Is an Essential Mediator of Prostate Cancer Bone Metastasis.

Authors:  Alvaro Gutierrez-Uzquiza; Cynthia Lopez-Haber; Danielle L Jernigan; Alessandro Fatatis; Marcelo G Kazanietz
Journal:  Mol Cancer Res       Date:  2015-05-28       Impact factor: 5.852

Review 7.  Protein kinase C in cancer: The top five unanswered questions.

Authors:  Mariana Cooke; Andrew Magimaidas; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Carcinog       Date:  2017-03-10       Impact factor: 4.784

8.  HepaCAM inhibits clear cell renal carcinoma 786-0 cell proliferation via blocking PKCε translocation from cytoplasm to plasma membrane.

Authors:  Bing Tan; Jinxiang Tan; Hongfei Du; Zhen Quan; Xiangdong Xu; Xiaoliang Jiang; Chunli Luo; Xiaohou Wu
Journal:  Mol Cell Biochem       Date:  2014-02-11       Impact factor: 3.396

9.  Differential regulation of cyclin D1 expression by protein kinase C α and ϵ signaling in intestinal epithelial cells.

Authors:  Marybeth A Pysz; Fang Hao; A Asli Hizli; Michelle A Lum; Wendy M Swetzig; Adrian R Black; Jennifer D Black
Journal:  J Biol Chem       Date:  2014-06-09       Impact factor: 5.157

10.  Transcriptional regulation of oncogenic protein kinase Cϵ (PKCϵ) by STAT1 and Sp1 proteins.

Authors:  HongBin Wang; Alvaro Gutierrez-Uzquiza; Rachana Garg; Laura Barrio-Real; Mahlet B Abera; Cynthia Lopez-Haber; Cinthia Rosemblit; Huaisheng Lu; Martin Abba; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.